DOI: 10.4244/EIJV16I10A146

Incorporating patients’ preferences into the Heart Team equation

Alec Vahanian1,2, MD; Marina Urena1,2,3, MD, PhD

Introduction

The Heart Team (HT) is essential when deciding upon the intervention in patients with valvular heart disease (VHD). There is evidence that patients express clear preferences for being involved in medical decision making. Unfortunately, the information patients can provide is overall underutilised1.

HT recommendations should be discussed with the patient, who can then make an informed decision taking into account his/her values and expectations in order to optimise patient-centred outcomes2.

Transcatheter aortic valve implantation (TAVI) will be used as an illustration in this editorial, because of the large clinical experience in this technique throughout the spectrum of surgical risk.

GENERAL PRINCIPLES

Patient-centred care requires that both the patient and the HT share information and work towards a consensus on decision making.

The choice between TAVI and surgical aortic valve replacement (SAVR) or medical therapy involves knowledge of the disease, making trade-offs between invasiveness of the procedure, immediate risks and benefits, and the balance between estimated life expectancy and prosthetic valve durability. This may be challenging given the remaining uncertainties in current data.

The validity of the patients’ preferences assumes the absence of significant cognitive impairment and the voluntary participation of the patient, because the patients’ wishes may differ from those estimated by their families or physicians. The former condition may justify the expertise of a geriatrician.

Finally, the burden of comorbidity is important. Patients should be made aware that symptoms that are not due to VHD will not improve after TAVI.

Besides patients and family, the “global network of care” must be involved in the process, including the HT members, the attending cardiologist, the general practitioner (GP) and, importantly, the nurses who deal closely with the patients.

Key factors are communication, the provider-patient relationship and trust, in which patients are empowered to question therapeutic options.

The assessment of patients’ preferences is a long and difficult process which requires time and patience.

PATIENTS’ PREFERENCES

Patients’ preferences for their involvement in decision making can be divided into a preference for information about the disease and treatment, and the desire to participate in the decision-making process. Information preferences are reported to be high in most patients, while there is variability regarding participation preferences (Figure 1).

Figure 1. Integrating patient preference into the Heart Team decision.

INFORMATION PREFERENCES

A normative “one size fits all” approach is not the best recipe to meet patients’ preferences, which are very heterogeneous. This heterogeneity is due to differences in: i) education, which is “culturally sensitive” between specific regions, ii) awareness about VHD and its treatment in the general population, iii) the influence of the physician, since “paternalistic physicians” tend to expect a more passive role from the patients, and iv) socio-economic factors. Appropriate stewardship of economic resources is an important responsibility of the HT. Another difference is v) clinical conditions; even in “high-income countries” the most deprived patients receive less care. Age is a key factor today in the TAVI field. Elderly patients prefer symptomatic benefit over increased survival. Severity of heart failure symptoms influences patients’ willingness to accept risks.

PARTICIPATION IN THE DECISION

A few studies have shown that patients’ preferences may lead the decision-making process in as many as 40% of cases3.

Within the elderly population currently referred for TAVI, a large proportion of patients prefers TAVI over SAVR because they place great value on the benefits of TAVI and are willing to tolerate uncertainties about durability4.

The agreement between the proposal from the HT and patients’ preferences may be easy in younger patients at low risk for surgery who accept surgery, elderly patients who are good candidates for TAVI and prefer TAVI and, finally, those for whom TAVI is obviously futile.

In other cases, reaching a consensus may be difficult or even impossible. The decision is most challenging in patients for whom there are uncertainties about evidence, but this is also the situation when patients’ engagement is needed the most. This scenario may happen in two sets of patients. It may occur in younger patients at low risk for surgery, without adverse conditions for TAVI, who do not want to be operated, accepting the risk of reintervention and the more frequent need for pacemaker implantation, given the lower initial risks and a more rapid return to full activity. This scenario is likely to be increasingly frequent and requires in-depth discussion during which several members of the HT share information with the patient5. It may also occur in patients at high/prohibitive risk where there is no firm line drawn between those who should or should not receive the treatment. Ascertaining benefit versus futility in individual patients is a difficult and multifaceted problem requiring collective judgement6.

The divergence of opinions might be bidirectional.

1) Physicians report patients’ preference as the most common reason to select medical management, despite the opinion of the HT. In up to 40% of cases, the HT recommends an intervention which is refused by the patient3,7. Interestingly, it has been shown that patients receiving medical treatment may complain afterwards about receiving insufficient information concerning intervention or surgery – less engagement by their physicians in the decision – and are more prone to believe that the final decision was not the best one. For these patients, the consensus in favour of intervention should be eagerly sought by the HT if TAVI is estimated at an acceptable risk level and an important benefit is expected.

2) Less frequently, patients may want an intervention which is refused by the HT. In this case, a cautious and comprehensive discussion concerning the patient and family expectations would be needed. Many of these patients will benefit from palliative care consultation.

In such patients, the evaluation of futility could be a dynamic process. There are ongoing trials investigating the effect of prehabilitation strategies (TAVR frailty; TAVR prehab).

In both scenarios, the lack of consensus raises an ethical question about the right of the HT to refuse a treatment modality, if a patient is adequately informed about treatment options and outcomes.

FUTURE PERSPECTIVES

Patient awareness of valvular heart disease is far from being satisfactory and is only slowly improving over time8. Awareness campaigns on VHD, such as European Heart Valve Disease Awareness initiatives ([email protected]; https://heartvalvecouncil.org) or the Valve for Life initiative by the EAPCI9, are helpful to raise awareness of aortic stenosis.

HT members must understand better the importance of patient-centred outcomes and improve their knowledge and skills in shared decision making. Communication skills are an important aspect (including empathy, language, use of educational videos) during in-hospital and after discharge consultations. Tools have been developed to enhance active participation in informed shared decision making (https://valveadvice.org/about-us; https://www.cardiosmart.org/TAVR DecisonAids)10.

Further research is needed to identify and weigh the importance of patient preference and to evaluate the effects of educational interventions.

Conclusion

“Incorporating patients’ preferences into the HT equation” is important in the TAVI era. This aspect significantly complements the individualised evaluation of the clinical, anatomical, and procedural aspects. Such a patient-centred approach is likely to enhance the active participation of patients in decisions concerning their health and improve the outcomes.

Conflict of interest statement

A. Vahanian is a consultant for CardioValve. M. Urena has no conflicts of interest to declare.

Supplementary data

To read the full content of this article, please download the PDF.


References

Volume 16 Number 10
Nov 20, 2020
Volume 16 Number 10
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV15I12A191 Dec 20, 2019
The role of the Heart Team in the planning of aortic valve replacement
Costa G et al
free

Editorial

10.4244/EIJ-E-23-00065 Jan 15, 2024
Aortic stenosis management: current evolution and future challenges
Scotti A and Latib A
free

10.4244/EIJV16I10A148 Nov 20, 2020
TAVI in patients with reduced life expectancy
Baumbach A and Mullen M
free

10.4244/EIJV15I14A217 Feb 20, 2020
Will your Heart Team EXCEL?
Mylotte D and Soo A
free

10.4244/EIJV15I10A155 Nov 15, 2019
Heart Team 2.0
Reardon MJ et al
free

10.4244/EIJV12I1A236 Dec 20, 2016
Patient selection for transcatheter or surgical intervention: the Heart Team TRUMPS the STS
Mylotte D and Piazza N
free

AORTIC VALVE INTERVENTIONS

10.4244/EIJV12SYA9 Sep 18, 2016
TAVI device selection: time for a patient-specific approach
Lee M et al
free
Trending articles
225.68

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
105.78

Expert consensus

10.4244/EIJ-E-22-00018 Dec 4, 2023
Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations
Lunardi M et al
free
77.85

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
68.7

Clinical research

10.4244/EIJ-D-21-00545 Sep 20, 2022
Coronary lithotripsy for the treatment of underexpanded stents: the international; multicentre CRUNCH registry
Tovar Forero M et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
45.3

Clinical research

10.4244/EIJ-D-18-01126 Aug 29, 2019
New-generation mechanical circulatory support during high-risk PCI: a cross-sectional analysis
Ameloot K et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved